20th Anniversary Medical Technologies 2015 Event to Focus on Future of Industry
Technology in the health care industry has continuously evolved to house state-of-the-art equipment, solutions and medical devices. From diagnosis to curing a patient, medical technologies prevent disease progression, add healthy life years and are overall a vital role in health care.
Frost & Sullivan – the global growth consulting firm providing market research and analysis – is leading the discussion on the future of medical technology by hosting the 20th Anniversary Medical Technologies 2015.
The event, set to take place from March 8-10, 2015, will connect health care leaders to explore how best to navigate transformation and prosper in a radically new health care landscape.
Medical device, health care and pharmaceutical pioneers Boston Scientific, Cleveland Clinic Innovations, Johnson & Johnson Diabetes Solutions, Sanovas and Medtronics are just a few companies planning to discuss strategy and best practices.
Additional companies that will be present to question and benchmark with are:
- Samsung: Applying Technologies to Engage Patients in Their Care
- Bayer Healthcare: State-of-the-Art Strategies on Digital Health
- Philips Healthcare: How Health Care Policy Applies to Your Company
- West Health: Innovating Health Care Delivery
According to the vice president of global government affairs, regulations and standards at Philips Healthcare, the event is an “awesome networking opportunity to engage with leaders in the industry.”
“It’s a great chance to hear current thought leaders in this dramatically changing industry and imprint key ideas through small group interactions,” said the vice president of commercial innovation, Given Imaging Inc.
The 20th Anniversary Medical Technologies 2015: A Frost & Sullivan Executive MindXchange will be hosted at the Hilton San Diego Resort and Spa.
For more information and to register for the event, visit here.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”